Verrica CMO buys 6,230 shares near $4.91

Verrica Pharmaceuticals Inc. (VRCA) reported that its Chief Medical Officer, Noah L. Rosenberg, purchased common stock in two open-market or private transactions.

Rhea-AI Filing Summary

Verrica Pharmaceuticals Inc. (VRCA) reported that its Chief Medical Officer, Noah L. Rosenberg, purchased common stock in two open-market or private transactions. On 2026-08-17, he bought 4,200 shares at a weighted average price of about $4.91 per share, and on 2026-08-18 he bought 2,030 shares at a weighted average price of about $4.92 per share. The prices for each trade reflect weighted averages of multiple executions between $4.90 and $4.95 per share.

Insider Trade Summary

Net Buyer: 6,230 shares

Net Buy 2 txns

Insider Rosenberg Noah L.

Role CMO

Bought 6,230 shs ($31K)

Type	Security	Shares	Price	Value
Purchase	Common Stock F1	2,030	$4.92	$10K
Purchase	Common Stock F1	4,200	$4.91	$21K

Holdings After Transaction: Common Stock — 8,587 shares (Direct)

Footnotes (1)

1. F1. The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.90 to $4.95 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

Key Figures

Shares purchased 2026-08-17: 4,200 shares Weighted average price 2026-08-17: $4.91 per share Shares purchased 2026-08-18: 2,030 shares +3 more

6 metrics

Shares purchased 2026-08-17 4,200 shares Common Stock bought by CMO in open-market or private transaction

Weighted average price 2026-08-17 $4.91 per share Multiple executions ranging from $4.90 to $4.95 inclusive

Shares purchased 2026-08-18 2,030 shares Common Stock bought by CMO in open-market or private transaction

Weighted average price 2026-08-18 $4.92 per share Multiple executions ranging from $4.90 to $4.95 inclusive

Total shares purchased 6,230 shares Sum of reported VRCA purchases on 2026-08-17 and 2026-08-18

Price range for executions $4.90–$4.95 per share Range of individual trade prices for both reported purchases

Key Terms

weighted average price, open market or private transaction, beneficial ownership

3 terms

weighted average price financial

"The price reported is a weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

open market or private transaction financial

"Purchase in open market or private transaction"

beneficial ownership financial

"full information regarding the number of shares purchased at each separate price"

Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions were reported for VRCA by Noah L. Rosenberg?

Noah L. Rosenberg, CMO of Verrica Pharmaceuticals, reported two open-market purchases of common stock totaling 6,230 shares at weighted average prices around $4.91–$4.92 per share, executed on 2026-08-17 and 2026-08-18.

How many VRCA shares did the CMO buy on 2026-08-17 and at what price?

On 2026-08-17, Verrica’s CMO purchased 4,200 VRCA shares at a weighted average price of $4.91 per share, with individual trade prices ranging from $4.90 to $4.95 inclusive.

What VRCA share purchase did the CMO make on 2026-08-18?

On 2026-08-18, Verrica’s CMO purchased 2,030 shares of VRCA common stock at a weighted average price of $4.92 per share, based on multiple executions between $4.90 and $4.95 inclusive.

What is the total number of VRCA shares bought in these reported insider transactions?

Across the two reported transactions, the CMO acquired a total of 6,230 shares of Verrica Pharmaceuticals common stock, purchased in the open market or private transactions at weighted average prices just under $5.00 per share.

Were the recent VRCA insider purchases under a Rule 10b5-1 plan?

The filing indicates the Rule 10b5-1 checkbox is not marked, so these purchases are not reported as being made under an affirmatively disclosed Rule 10b5-1 trading plan, based on the document’s structured data.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/18/2026 - 05:01 PM Accepted by SEC EDGAR 08/18/2026 - 05:00 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Rosenberg Noah L.

(Last) (First) (Middle)

C/O VERRICA PHARMACEUTICALS INC.

44 W. GAY ST., SUITE 400

(Street)

WEST CHESTER PENNSYLVANIA 19380

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Verrica Pharmaceuticals Inc. [ VRCA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CMO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/17/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/17/2026		P		4,200	A	$4.91(1)	6,557	D
Common Stock	08/18/2026		P		2,030	A	$4.92(1)	8,587	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.90 to $4.95 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

	/s/ Jayson Rieger, Attorney-in-Fact	08/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)